ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,069.39
-0.24%
US Tech 100
21,088.60
-0.51%
다우존스 지수
44,185.52
0.08%
Bitcoin
101,250.85
0.06%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Inhibrx Biosciences Inc (INBX) 시세

Inhibrx Biosciences Inc

Inhibrx Biosciences Inc (INBX)

NASDAQ
15.12
0.00
( 0.00% )
업데이트: 23:31:56
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
15.12
매수가
14.77
매도가
14.97
거래량
54
0.00 일간 변동폭 0.00
10.80 52주 범위 39.79
market_cap
218.876M
전일 종가
15.12
개장가
-
최근 거래 시간
25
@
14.88
마지막 거래 시간
23:31:23
재정 규모
-
VWAP
-
평균 볼륨(3m)
79,669
발행 주식
14,475,904
배당수익률
-
주가수익률
-1.48
주당순이익(EPS)
-10.71
매출
1.63M
순이익
-154.96M

Inhibrx Biosciences Inc 정보

We are a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. We are a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence.

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.inhibrx.com
본부
Wilmington, Delaware, USA
설립됨
-
Inhibrx Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker INBX. The last closing price for Inhibrx Biosciences was US$15.12. Over the last year, Inhibrx Biosciences shares have traded in a share price range of US$ 10.80 to US$ 39.79.

Inhibrx Biosciences currently has 14,475,904 shares in issue. The market capitalisation of Inhibrx Biosciences is US$218.88 million. Inhibrx Biosciences has a price to earnings ratio (PE ratio) of -1.48.

INBX 최신 뉴스

추가 뉴스

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results PR Newswire SAN DIEGO, Nov. 14, 2024 SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx...

15 11월 2024
PR Newswire (US)

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation PR Newswire SAN DIEGO, Nov. 4, 2024 SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc...

05 11월 2024
PR Newswire (US)

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO, Aug. 13, 2024 SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx...

14 8월 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

01 6월 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

31 5월 2024
Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

31 5월 2024
Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

31 5월 2024
Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

31 5월 2024
Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

31 5월 2024
Edgar (US Regulatory)

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

31 5월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.13-0.85245901639315.251614.7156602915.16142517CS
4-0.47-3.0147530468215.5916.212.258431014.59655998CS
12-2.1-12.195121951217.2217.612.257966915.38228492CS
26-1.41-8.5299455535416.5317.7910.811003214.69104652CS
52-9.74-39.179404666124.8639.7910.839809531.85382639CS
156-24.16-61.507128309639.2845.9897.6742825425.33093898CS
260-4.58-23.248730964519.750.977.6734470925.89712042CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AALAmerican Airlines Group Inc
US$ 17.58
(0.00%)
404.66k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 70.29
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.42
(0.00%)
1.44k
AACGATA Creativity Global
US$ 0.868259
(0.00%)
15
AALAmerican Airlines Group Inc
US$ 17.58
(0.00%)
404.66k
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 70.29
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.42
(0.00%)
1.44k
AACGATA Creativity Global
US$ 0.868259
(0.00%)
15
CDTConduit Pharmaceuticals Inc
US$ 0.0883
(0.00%)
57.95M
LAESSEALSQ Corporation
US$ 1.15
(0.00%)
55.02M
PALIPalisade Bio Inc
US$ 1.40
(0.00%)
27.32M
SYTASiyata Mobile Inc
US$ 0.748
(0.00%)
20.56M
TRVITrevi Therapeutics Inc
US$ 2.49
(0.00%)
17.48M

INBX Discussion

게시물 보기
Monksdream Monksdream 2 월 전
INBX under $20
👍️0
Monksdream Monksdream 3 월 전
INBX under $20
👍️0
Monksdream Monksdream 3 월 전
INBX under $15
👍️0
Monksdream Monksdream 8 월 전
INBX over $30
👍️0
TrendTrade2016 TrendTrade2016 2 년 전
heres the dolla...boom!!
👍️0
TrendTrade2016 TrendTrade2016 2 년 전
INBX DOLLA RUMMER IN PROCESS
👍️0
TrendTrade2016 TrendTrade2016 2 년 전
INBX...PRE MARKET VOL
👍️0
Jaydixson1 Jaydixson1 2 년 전
Seems to be dropping
👍️0
make it happen make it happen 2 년 전
Numbers do not make sense. They need to raise so much to keep the Phases going. So much debt and money burn with worse quarters and barley any revs. Not bashing it's just what it is. 1,000's of percent's negative on profit. Revenue $0.18 Book Value -$0.12. Also imo this volume isn't sustainable 9 times normal as of now

Profitability
Profit Margin 0.00%
Operating Margin -1,448.76%

Management Effectiveness
Return on Assets -37.98%
Return on Equity -562.25%

Income Statement
Revenue 7.03M
Revenue Per Share 0.18
Quarterly Revenue Growth (yoy) -25.50%
Gross Profit -64.21M
EBITDA -100.6M
Net Income Avi to Common -110.75M
Diluted EPS -2.44

Balance Sheet
Total Debt 175.7M
Book Value Per Share -0.13

Cash Flow Statement
Operating Cash Flow -90.16M
Levered Free Cash Flow -46.31M
👍️0

최근 히스토리

NASDAQ
INBX
Inhibrx Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유